Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre

Wann, Alysson; Ashley, David M.; Khasraw, Mustafa

doi:10.1007/s00520-016-3124-3

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drugs that we studied are indicated in patients with advanced cancer and may even be introduced in the last months of their life . This fragile population of patients is regularly hospitalized as part of the evolution of their disease.…”

Section: Discussionmentioning

confidence: 99%

Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database

Quillet

Colin

Bourgeois

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The aim of this study was to assess an automated detection method of serious adverse reactions induced by oral targeted therapy (OTT) in patients with cancer, performed in the French Diagnosis Related Groups (DRG) database. Patients with cancer of the Poitiers hospital who started an OTT between 2014 and 2015 were included. This study focused on adverse drug reaction which required inpatient hospitalization (ADR ). All diagnoses coded in the DRG database for hospital stays that occurred within 3 months after OTT initiation were collected (potential ADR ). Filters (exclusion criteria) were automatically applied on potential ADR to exclude diagnoses that were not adverse drug reactions (false positives). A pharmacovigilance review was carried out to identify ADR in the medical records (reported ADR ). The sensitivity and specificity of the detection method were estimated for each filter combinations by comparison between potential and reported ADR . This study included 129 patients. The medical records review led to identify 19 ADR (all coded in the DRG database) in 14 patients. To maintain a 100% sensitivity of the method detection, the best specificity obtained was 58.3% (95% IC: [55.2-61.4]).The use of restrictive filters ('drug' in the diagnostic label, specific diagnosis code for adverse cancer drug reaction) resulted in a 97.8% specificity (95% IC: [96.6-98.5]) with a 38.2% sensitivity (95% IC: [23.9-55.0]). Our method has detected the third of ADR with an excellent specificity. Complementary experimentations in pharmacovigilance centers are necessary to evaluate the interest of this tool in routine in addition to spontaneous reporting.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database

Quillet

Colin

Bourgeois

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre

Abstract: The use of targeted therapy at the end of life in this single-centre descriptive study was lower than documented in other studies. There is a need to prospectively document the factors leading to this prescribing behaviour to guide future protocols.

Cited by 1 publication

References 22 publications

Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database

Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database

Contact Info

Product

Resources

About